C-VLCMReneuBio
small molecules, neural stem cells, aged brain screening
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-VLCM
C-VLCMC-VLCMsmall molecules, neural stem cells, aged brain screening
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ReneuBio states that aging reduces the brain’s regenerative capacity and that this loss contributes to age-related brain disorders becoming more prevalent. The company says it is developing medicines to restore the aging brain’s ability to heal, specifically by using small molecules to reactivate dormant neural stem cells and promote resilience in conditions such as chemobrain, stroke, and Alzheimer’s disease.
SourceReneuBio states that aging reduces the brain's regenerative capacity and that this decline contributes to increasingly prevalent neurological injuries and diseases in an aging population. The company says it aims to reverse that problem by developing breakthrough medicines that restore regeneration in the aging brain, specifically by enhancing neural stem cell function and using genetically validated in vivo targets to boost regeneration in the old brain.
Source